Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tema Cardiovascular and Metabolic ETF (HRTS)

Tema Cardiovascular and Metabolic ETF (HRTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Tema ETFs
  • Assets Under Management 54,699,500
  • Shares Outstanding, K 1,550
  • 60-Month Beta 0.97
  • Price/Earnings ttm 0.00
  • Annual Dividend & Yield 0.47 (1.33%)
  • Most Recent Dividend 0.469 on 12/11/24
  • Management Fee 0.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.03 +3.70%
on 12/10/25
36.20 -2.51%
on 11/26/25
+0.95 (+2.76%)
since 11/14/25
3-Month
29.54 +19.47%
on 09/26/25
36.20 -2.51%
on 11/26/25
+5.14 (+17.05%)
since 09/15/25
52-Week
25.32 +39.38%
on 04/09/25
36.20 -2.51%
on 11/26/25
+4.86 (+15.97%)
since 12/13/24

Most Recent Stories

More News
Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing

The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.

TCAF : 38.05 (-0.29%)
ASND : 213.24 (-3.26%)
IBB : 169.38 (-0.02%)
HRTS : 35.29 (+0.76%)
Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes

The company’s stock declined nearly 60% in 2024 and has lost an additional 21% in 2025, with this latest setback further dampening investor confidence.

VXF : 211.93 (-0.84%)
KROS : 21.23 (-1.30%)
HRTS : 35.29 (+0.76%)
XBI : 122.84 (-0.24%)
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, PPH, HRTS and THNR

For Immediate ReleaseChicago, IL – October 17, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

NVO : 50.37 (+0.38%)
LLY : 1,062.19 (+3.38%)
HRTS : 35.29 (+0.76%)
PPH : 102.64 (+1.84%)
THNR : 25.59 (+1.23%)
Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win

In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications, particularly GLP-1 receptor agonists such as Ozempic and Wegovy. The global...

NVO : 50.37 (+0.38%)
LLY : 1,062.19 (+3.38%)
HRTS : 35.29 (+0.76%)
PPH : 102.64 (+1.84%)
THNR : 25.59 (+1.23%)
Tap the Weight-Loss Drug Market With These ETFs

The weight-loss drug market is heating up with the introduction of GLP-1 pills. Novo Nordisk’s NVO Wegovy and Eli Lilly’s LLY Zepbound have been dominating this market and several other companies are...

NVO : 50.37 (+0.38%)
OZEM : 34.70 (+0.58%)
LLY : 1,062.19 (+3.38%)
HRTS : 35.29 (+0.76%)
RHHBY : 51.2200 (+2.36%)
THNR : 25.59 (+1.23%)
Not Sure Which Weight Loss Stock to Buy? Invest in This ETF

Many healthcare companies have been eagerly developing new weight loss drugs in an effort to cash in ...

VKTX : 36.15 (-2.51%)
LLY : 1,062.19 (+3.38%)
HRTS : 35.29 (+0.76%)
Don’t Know Which Weight-Loss Stock Will Be the Biggest Winner? Invest in This ETF Instead

There’s a lot of excitement in the weight-loss industry these days. Between Ozempic, Wegovy, Mounjaro, ...

NVO : 50.37 (+0.38%)
HRTS : 35.29 (+0.76%)
LLY : 1,062.19 (+3.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Fund Summary

The Tema Cardiovascular and Metabolic ETF seeks to provide long-term growth of capital by investing in companies leading the fight against diabetes, obesity and cardiovascular diseases.

See More

Top 10 Holdings

Name % Holdings

See More

Key Turning Points

3rd Resistance Point 35.49
2nd Resistance Point 35.41
1st Resistance Point 35.35
Last Price 35.29
1st Support Level 35.21
2nd Support Level 35.13
3rd Support Level 35.07

See More

52-Week High 36.20
Last Price 35.29
Fibonacci 61.8% 32.04
Fibonacci 50% 30.76
Fibonacci 38.2% 29.48
52-Week Low 25.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar